Royal Bank of Canada’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-249,138
| Closed | -$134K | – | 7411 |
|
|
2024
Q4 | $134K | Buy |
249,138
+187,381
| +303% | +$131K | ﹤0.01% | 5145 |
|
|
2024
Q3 | $109K | Buy |
61,757
+60,696
| +5,721% | +$84.7K | ﹤0.01% | 5290 |
|
|
2024
Q2 | $1K | Sell |
1,061
-1,227
| -54% | -$3.07K | ﹤0.01% | 6959 |
|
|
2024
Q1 | $21K | Sell |
2,288
-13,076
| -85% | -$127K | ﹤0.01% | 5908 |
|
|
2023
Q4 | $167K | Buy |
15,364
+8,507
| +124% | +$63.8K | ﹤0.01% | 5256 |
|
|
2023
Q3 | $55K | Sell |
6,857
-582
| -8% | -$4.84K | ﹤0.01% | 5736 |
|
|
2023
Q2 | $81K | Buy |
7,439
+6,983
| +1,531% | +$59.8K | ﹤0.01% | 5494 |
|
|
2023
Q1 | $3K | Buy |
456
+400
| +714% | +$2.51K | ﹤0.01% | 6725 |
|
|
2022
Q4 | $0 | Buy |
56
+4
| +8% | +$20 | ﹤0.01% | 7902 |
|
|
2022
Q3 | $0 | Buy |
52
+5
| +11% | +$31 | ﹤0.01% | 8022 |
|
|
2022
Q2 | $0 | Sell |
47
-2,269
| -98% | -$13.8K | ﹤0.01% | 7856 |
|
|
2022
Q1 | $21K | Sell |
2,316
-5,584
| -71% | -$55.5K | ﹤0.01% | 6592 |
|
|
2021
Q4 | $94K | Buy |
7,900
+4,593
| +139% | +$53K | ﹤0.01% | 5999 |
|
|
2021
Q3 | $38K | Buy |
3,307
+716
| +28% | +$9.85K | ﹤0.01% | 6332 |
|
|
2021
Q2 | $46K | Buy |
2,591
+153
| +6% | +$2.46K | ﹤0.01% | 6101 |
|
|
2021
Q1 | $38K | Buy |
2,438
+2,131
| +694% | +$30.8K | ﹤0.01% | 6061 |
|
|
2020
Q4 | $4K | Buy |
307
+229
| +294% | +$3.19K | ﹤0.01% | 6761 |
|
|
2020
Q3 | $1K | Sell |
78
-196
| -72% | -$1.69K | ﹤0.01% | 6507 |
|
|
2020
Q2 | $2K | Sell |
274
-4,053
| -94% | -$37.3K | ﹤0.01% | 6328 |
|
|
2020
Q1 | $35K | Buy |
4,327
+4,312
| +28,747% | +$37.4K | ﹤0.01% | 5319 |
|
|
2019
Q4 | $0 | Buy |
+15
| New | +$84 | ﹤0.01% | 7210 |
|
|
2019
Q3 | – | Sell |
-1,575
| Closed | -$26K | – | 7242 |
|
|
2019
Q2 | $26K | Sell |
1,575
-4
| -0.3% | -$69 | ﹤0.01% | 5585 |
|
|
2019
Q1 | $26K | Sell |
1,579
-50
| -3% | -$720 | ﹤0.01% | 5532 |
|
|
2018
Q4 | $19K | Sell |
1,629
-133
| -8% | -$2.69K | ﹤0.01% | 5622 |
|
|
2018
Q3 | $70K | Buy |
+1,762
| New | +$50.1K | ﹤0.01% | 5063 |
|
|
2017
Q3 | – | Sell |
-1
| Closed | – | – | 7058 |
|
|
2017
Q2 | $0 | Buy |
+1
| New | +$5 | ﹤0.01% | 6832 |
|
Royal Bank of Canada's MRNS Position: Q1 2025 in Review
Royal Bank of Canada sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 249,138 shares — an estimated $134K sold.
Royal Bank of Canada first reported a position in MRNS in Q2 2017 and held it in 26 quarters. The position peaked at $167K in Q4 2023. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.
- Royal Bank of Canada reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
- Royal Bank of Canada sold 249,138 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $134K.
- Royal Bank of Canada first reported a position in Marinus Pharmaceuticals, Inc in Q2 2017 and held it in 26 quarters.
- Royal Bank of Canada's Marinus Pharmaceuticals, Inc position peaked at $167K in Q4 2023.
- 0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.
Based on Royal Bank of Canada's 13F filing for Q1 2025, filed 15 May 2025.